Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.
about
Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behaviorAddition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysisOxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging.Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis.Incorporation of albumin fusion proteins into fibrin clots in vitro and in vivo: comparison of different fusion motifs recognized by factor XIIIa.Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigsCatalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings.Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Drug development for the management of organophosphorus poisoning.Tools to cope with difficult-to-express proteins.Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning.Recent advances in the treatment of organophosphorous poisonings.Chemical Polysialylation and In Vivo Tetramerization Improve Pharmacokinetic Characteristics of Recombinant Human Butyrylcholinesterase-Based Bioscavengers.Proline-Rich Chaperones Are Compared Computationally and Experimentally for Their Abilities to Facilitate Recombinant Butyrylcholinesterase Tetramerization in CHO Cells.
P2860
Q28393492-A42F6469-04C3-402C-9BC4-633888E3787AQ33414424-1F21DA87-3317-4D4A-AB08-0B6F83F5A4F2Q33951376-CF8BABA3-2F4A-4498-AE5A-5D8B5F66E6FCQ34096110-7D586EC7-5C3A-45F9-BB98-D65BF956700DQ34107034-125EFB3E-BB58-4428-9819-E7C74A084F92Q35175807-E4E3001C-B554-4B8D-A851-9C462DFED816Q35944247-0856056E-59EC-4748-9BF8-D15818954E27Q37428117-9425C5A4-FD45-41FC-A611-7066F2E06AA4Q38088357-4E921CF6-04E7-4B0E-BBCA-3A5D59F23B68Q38152506-2B1879B0-FB91-4B67-B122-FF8B31E6A33DQ38808506-0F828BF7-7A7A-4092-95CA-CEBD5195EA48Q39329265-73519724-DB0B-4DEA-92BD-45E2B9BD30D8Q42027845-981CA8FB-D299-4108-9171-8C3059F3C9BAQ42237480-C6B7F735-9DDA-465D-8747-8A8E9E118A29Q48197665-9732724C-8FC3-4D77-8D46-BF66E66341DF
P2860
Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Substantially improved pharmac ...... fusion to human serum albumin.
@ast
Substantially improved pharmac ...... fusion to human serum albumin.
@en
Substantially improved pharmac ...... fusion to human serum albumin.
@nl
type
label
Substantially improved pharmac ...... fusion to human serum albumin.
@ast
Substantially improved pharmac ...... fusion to human serum albumin.
@en
Substantially improved pharmac ...... fusion to human serum albumin.
@nl
prefLabel
Substantially improved pharmac ...... fusion to human serum albumin.
@ast
Substantially improved pharmac ...... fusion to human serum albumin.
@en
Substantially improved pharmac ...... fusion to human serum albumin.
@nl
P2093
P2860
P356
P1433
P1476
Substantially improved pharmac ...... fusion to human serum albumin.
@en
P2093
Annie Bellemare
Annie S Bilodeau
Anthoula Lazaris
Carl Turcotte
Costas N Karatzas
David E Lenz
Douglas M Cerasoli
Duncan K Hockley
Eric Brochu
P2860
P2888
P356
10.1186/1472-6750-8-50
P577
2008-05-16T00:00:00Z
P5875
P6179
1042517364